These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37805238)

  • 1. The Emulated Targeted Trial: A Causal, But Never Casual, Surrogate for Randomized Clinical Trials.
    Wendel-Garcia PD; Bos LDJ
    Chest; 2023 Oct; 164(4):816-817. PubMed ID: 37805238
    [No Abstract]   [Full Text] [Related]  

  • 2. Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.
    Weir IR; Rider JR; Trinquart L
    Pharm Stat; 2022 Jan; 21(1):163-175. PubMed ID: 34346173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
    Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
    Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating Causal Effects of Treatment in a Randomized Trial When Some Participants Only Partially Adhere.
    Shrier I; Platt RW; Steele RJ; Schnitzer M
    Epidemiology; 2018 Jan; 29(1):78-86. PubMed ID: 29023241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference.
    Alonso A; Van der Elst W; Molenberghs G; Buyse M; Burzykowski T
    Biometrics; 2016 Sep; 72(3):669-77. PubMed ID: 26864244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogacy marker paradox measures in meta-analytic settings.
    Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
    Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints.
    Gabriel EE; Sachs MC; Gilbert PB
    Stat Med; 2015 Feb; 34(3):381-95. PubMed ID: 25352131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating causal effect with randomized controlled trial.
    Shrier I
    Epidemiology; 2013 Sep; 24(5):779-81. PubMed ID: 23903885
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials.
    Wallach JD; Deng Y; Polley EC; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Jeffery MM; Lyon TD; Ross JS; McCoy RG
    Clin Trials; 2023 Dec; 20(6):689-698. PubMed ID: 37589143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the causal structure of information bias and confounding bias in randomized trials.
    Shahar E; Shahar DJ
    J Eval Clin Pract; 2009 Dec; 15(6):1214-6. PubMed ID: 20367730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals.
    Dahabreh IJ; Robertson SE; Tchetgen EJ; Stuart EA; Hernán MA
    Biometrics; 2019 Jun; 75(2):685-694. PubMed ID: 30488513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population.
    Dahabreh IJ; Haneuse SJA; Robins JM; Robertson SE; Buchanan AL; Stuart EA; Hernán MA
    Am J Epidemiol; 2021 Aug; 190(8):1632-1642. PubMed ID: 33324969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal stratification--a goal or a tool?
    Pearl J
    Int J Biostat; 2011 Mar; 7(1):20. PubMed ID: 21556288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency and robustness of causal effect estimators when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS
    Stat Med; 2018 Dec; 37(28):4126-4141. PubMed ID: 30109713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive cluster level surrogacy in the presence of interference.
    Gabriel EE; Follmann DA
    Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal inference in randomized clinical trials.
    Zheng C; Dai R; Gale RP; Zhang MJ
    Bone Marrow Transplant; 2020 Jan; 55(1):4-8. PubMed ID: 30914756
    [No Abstract]   [Full Text] [Related]  

  • 20. Causal inference from randomized trials in social epidemiology.
    Kaufman JS; Kaufman S; Poole C
    Soc Sci Med; 2003 Dec; 57(12):2397-409. PubMed ID: 14572846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.